BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne presented broad positive solid tumor data at ESMO 2026, headlined by its first-in-class GPC3 x 4-1BB bispecific BGB-B2033 hitting a 36.0% confirmed ORR at the recommended Phase 3 dose in heavily pretreated hepatocellular carcinoma, versus roughly 5% for TKIs in the late-line setting. First-in-human data also impressed in NSCLC: the brain-penetrant PRMT5 inhibitor BGB-58067 posted a 25.3% confirmed ORR in MTAP-deficient disease with 7.7-month median PFS and 30.8% intracranial ORR in brain metastases, while the CEA-targeting ADC BG-C477 achieved a 56.0% ORR in CEA-high NSCLC.
Key figures
- Drug Name
- BGB-B2033, BGB-58067, BG-C477, BGB-43395
- Phase Of Trial
- Phase 1 (BGB-B2033, BGB-58067, BG-C477); Phase 3 (KANDELA-302)
- Grade3plus trae bgb b2033
- 5.3%
- Intracranial orr bgb 58067
- 30.8%
- Orr cea adc cea high nsclc
- 56.0%
- Late stage development timing
- BGB-58067 and BG-C477 in 2027
- Orr prmt5 inhibitor mtap nsclc
- 25.3%
- Orr gpc3 bispecific phase3 dose
- 36.0%
- Registrational hcc trials timing
- initiation by end of 2026
- Median pfs bgb 58067 nsclc months
- 7.7
- Duration of response 6mo bgb b2033
- 74.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.